Dr. Ali on the Future of Adjuvant Care for HER2+ Breast Cancer

Haythem Y. Ali, MD
Published: Thursday, Jun 21, 2018



Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Ali says that a strong adjuvant strategy that is currently being used is de-escalating to single chemotherapy with trastuzumab (Herceptin). Prior attempts to lengthen the time of trastuzumab has not been shown to be beneficial in the adjuvant setting.

Another new adjuvant strategy is T-DM1 (ado-trastuzumab emtansine; Kadcyla). Ali says that T-DM1 will likely be useful in patients who do not achieve a complete response in the neoadjuvant setting. Trials are currently ongoing with the agent.

In the metastatic setting, there are tyrosine kinase inhibitors that are more selective than neratinib (Nerlynx), with a more favorable toxicity profile, Ali says. If these agents are successful, they may be used in the adjuvant setting.
SELECTED
LANGUAGE


Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Ali says that a strong adjuvant strategy that is currently being used is de-escalating to single chemotherapy with trastuzumab (Herceptin). Prior attempts to lengthen the time of trastuzumab has not been shown to be beneficial in the adjuvant setting.

Another new adjuvant strategy is T-DM1 (ado-trastuzumab emtansine; Kadcyla). Ali says that T-DM1 will likely be useful in patients who do not achieve a complete response in the neoadjuvant setting. Trials are currently ongoing with the agent.

In the metastatic setting, there are tyrosine kinase inhibitors that are more selective than neratinib (Nerlynx), with a more favorable toxicity profile, Ali says. If these agents are successful, they may be used in the adjuvant setting.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x